好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Strategizing Clinical Trial Recruitment in the Digital Age
Research Methodology, 好色先生, and History
P1 - Poster Session 1 (5:30 PM-6:30 PM)
4-072
To identify advantages of Parkinson’s disease (PD) clinical trial recruitment through social media and optimizing its use by sites and sponsors.

Clinical trials in Parkinson’s disease  have traditionally used mass media to advertise for clinical trials.  Transitioning to social media may be more advantageous for timely recruitment.  

At our institute, a recruitment committee provided guidelines to optimize social media use for clinical trial enrollment.

 

Social media as compared to mass media is quick, cost effective and reaches a targeted audience worldwide. Social media interface allows measurability of viewership and tracks progress of potential participants, from screening to enrollment. It allows participants to express immediate interest by completing prescreening questionnaire. Social media platforms directly approach users with relevant trial information while browsing their user profile.

 

Recommendations for sites and sponsors:

  • 1. Adequate budget earmarked for designing, regulatory approval and advertising for clinical trials on social media.

  • 2.Review social media sites to identify online patient communities.
  • 3. Sponsors may interact with patient advocacy groups via social media and discussion boards to post press releases and provide links to clinical trial information. They may regularly post e- newsletters to keep patients engaged.

  • 4. Advertising on Google, Facebook and YouTube with web links to the clinical trial website.

  • 5. Implement a twitter campaign aimed at raising research awareness.

  • 6. Identify key hashtags and regular online disease state chats, which can help design patient friendly  social media content.

  • 7. Use disease state blogs to plan effective recruitment campaigns.

  • 8. Sponsors can collaborate to create disease specific clinical trial applications which features all ongoing clinical trials in that area.

Site and sponsors need to transition from mass to social media for effective clinical trial recruitment. They should consider several different social media platforms to target different demographic groups which may improve recruitment of hard to reach  minority populations and increase diversity in PD clinical trials.
Authors/Disclosures
Pinky H. Agarwal, MD, FAAN (Evergreen Health)
PRESENTER
Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals Inc. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion Pharmaceuticals. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Supernus. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal. Dr. Agarwal has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Agarwal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AskBio. An immediate family member of Dr. Agarwal has stock in ALDEYRA THERAPEUTICS INC. An immediate family member of Dr. Agarwal has stock in Curis Inc. An immediate family member of Dr. Agarwal has stock in Citius Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Fortress Biotech. An immediate family member of Dr. Agarwal has stock in TG Therapeutics. An immediate family member of Dr. Agarwal has stock in ATYR PHARMA INC . An immediate family member of Dr. Agarwal has stock in CORVUS PHARMACEUTICALS INC . An immediate family member of Dr. Agarwal has stock in LAVA THERAPEUTICS . An immediate family member of Dr. Agarwal has stock in OVID THERAPEUTICS INC . An immediate family member of Dr. Agarwal has stock in TERNS PHARMACEUTICALS INC. An immediate family member of Dr. Agarwal has stock in VIKING THERAPEUTICS INC. Dr. Agarwal has stock in WAVE LIFE SCIENCES LTD. An immediate family member of Dr. Agarwal has stock in ProQr Therapeutics. An immediate family member of Dr. Agarwal has stock in Mind Medicine. An immediate family member of Dr. Agarwal has stock in Lyra Therapeutics. An immediate family member of Dr. Agarwal has stock in Larimer Therapeutics. An immediate family member of Dr. Agarwal has stock in Lantern Pharma. An immediate family member of Dr. Agarwal has stock in Black Diamond Therapeutics. An immediate family member of Dr. Agarwal has stock in Amylyx Pharma. An immediate family member of Dr. Agarwal has stock in Palisade Bio. An immediate family member of Dr. Agarwal has stock in Inozyme Pharma. An immediate family member of Dr. Agarwal has stock in Pyxis Oncology. An immediate family member of Dr. Agarwal has stock in Vertex Pharmaceuticals. An immediate family member of Dr. Agarwal has stock in Vyne Therapeutics. An immediate family member of Dr. Agarwal has stock in Reviva Pharmaceuticals Hld. An immediate family member of Dr. Agarwal has stock in Immuneering Corp. An immediate family member of Dr. Agarwal has stock in Imunon Inc. An immediate family member of Dr. Agarwal has stock in Enlivex Therapeutics. An immediate family member of Dr. Agarwal has stock in Candel Therapeutics. An immediate family member of Dr. Agarwal has stock in Applied Digital Corp. An immediate family member of Dr. Agarwal has stock in Atai Life Sciences. An immediate family member of Dr. Agarwal has stock in Adma Biologics. The institution of Dr. Agarwal has received research support from Biogen . The institution of Dr. Agarwal has received research support from CHDI Foundation. The institution of Dr. Agarwal has received research support from Eli Lilly. The institution of Dr. Agarwal has received research support from MJ Fox. The institution of Dr. Agarwal has received research support from Roche . The institution of Dr. Agarwal has received research support from Supernus. The institution of Dr. Agarwal has received research support from Nova Nordisc. The institution of Dr. Agarwal has received research support from Inhibikase. The institution of Dr. Agarwal has received research support from Intracellular therapeurtics.
No disclosure on file
Daniel J. Burdick, MD, FAAN (EvergreenHealth Medical Center) Dr. Burdick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Praxis Precision Medicines. The institution of Dr. Burdick has received research support from AbbVie. The institution of Dr. Burdick has received research support from Athira. The institution of Dr. Burdick has received research support from Cerevel. The institution of Dr. Burdick has received research support from Merck. The institution of Dr. Burdick has received research support from Neuraly. The institution of Dr. Burdick has received research support from Pharma 2B. The institution of Dr. Burdick has received research support from Jazz Pharmaceuticals. The institution of Dr. Burdick has received research support from Praxis. The institution of Dr. Burdick has received research support from Sage Therapeutics. The institution of Dr. Burdick has received research support from Biogen. The institution of Dr. Burdick has received research support from Cerevance. The institution of Dr. Burdick has received research support from UCB.